Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q4 FY26 results · Jan–Mar 2026
Glenmark Pharmaceuticals reported revenue from operations of ₹3,770.59 crore (up 15.8% from Q4 FY25) and net profit of ₹301.32 crore (up 6773.2% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,770.59 | 3,256.21 | +15.8% | 3,900.61 | −3.3% |
| Other income | 189.08 | 11.69 | 16x | 44.47 | +325.2% |
| Total income | 3,959.67 | 3,267.89 | +21.2% | 3,945.08 | +0.4% |
| Profit before tax | 387.77 | 7.97 | 49x | 534.00 | −27.4% |
| Net profit for the period | 301.32 | 4.38 | 69x | 403.23 | −25.3% |
| Attributable to shareholders of the company | (0.10) | 4.65 | Turned loss | 403.21 | Turned loss |
| EPS, basic (₹) | 10.68 | 0.16 | 67x | 14.29 | −25.3% |
| Net margin (%) | 8.0 | 0.1 | 10.3 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,146.58 | 2,009.49 | +6.8% | 2,359.93 | −9.0% |
| Other income | 307.88 | 88.45 | +248.1% | 109.06 | +182.3% |
| Total income | 2,454.45 | 2,097.95 | +17.0% | 2,468.99 | −0.6% |
| Profit before tax | (107.40) | 181.16 | Turned loss | 346.53 | Turned loss |
| Net profit for the period | (73.90) | 147.76 | Turned loss | 282.07 | Turned loss |
| EPS, basic (₹) | (2.62) | 5.24 | Turned loss | 10.00 | Turned loss |
| Net margin (%) | -3.4 | 7.4 | 12.0 |
Consolidated
- Filed with BSE
- 11 Jun 2026, 16:53 IST
- Board meeting
- 29 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Jun 2026, 16:53 IST
- Board meeting
- 29 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE